首页> 美国卫生研究院文献>International Journal of Neuropsychopharmacology >Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010
【2h】

Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010

机译:抗抑郁药治疗期间的心血管不良反应:1993年至2010年间德语国家的药物监测报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:Antidepressants (ADs) are known to have the potential to cause various cardiovascular adverse drug reactions (ADRs). The tricyclic antidepressants (TCAs) were first revealed to be a possible source of cardiovascular ADRs. In recent years, newer classes of ADs were also suggested to have a higher risk of cardiovascular adverse effects. In particular, the selective serotonin reuptake inhibitors (SSRIs) were suspected to have the potential to induce QTc interval prolongation, and therefore increase the risk of ventricular arrhythmia. This descriptive study is based on the continuous pharmacovigilance program of German-speaking countries (Austria, Germany, and Switzerland), the Arzneimittelsicherheit in der Psychiatrie (AMSP), which assesses severe ADRs occurring in clinical routine situations.
机译:背景:已知抗抑郁药(AD)可能引起各种心血管不良药物反应(ADR)。首先发现三环类抗抑郁药(TCA)是心血管ADR的可能来源。近年来,也有人建议新型的AD具有更高的心血管不良反应风险。特别是,选择性5-羟色胺再摄取抑制剂(SSRIs)被怀疑具有诱导QTc间隔延长的潜力,因此增加了室性心律失常的风险。这项描述性研究基于德语国家(奥地利,德国和瑞士)的持续药物警戒计划,精神病院的Arzneimittelsicherheit(AMSP),该计划评估了在临床常规情况下发生的严重ADR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号